Category: Stakeholder news and views
The European Health Data Space Regulation is a reality
The European Health Data Space (EHDS) Regulation has made it to the EU’s Official Journal, almost three years after the initial proposal was published.
The new EU clinical trials map is online
A new clinical trial map was launched by EMA as part of the Clinical Trials Information System (CTIS) on March 3.
From bedside to Brussels: hematology at the forefront of EU health policy
EHA's experts are currently front and center in several important EU initiatives that will help improve conditions for, and patient access to, innovation in hematology.
Addressing immunoglobulin shortages: EHA and EBA’s strategic recommendations at …
In recent years, shortages of immunoglobulins (Ig) have become a growing concern in the European Union (EU).
Collaboration with the EMA on Joint Clinical Assessments and Joint Scientific Co…
The European Hematology Association (EHA) welcomes the draft Implementing Act laying down procedural rules for the exchange of information between the Health Technology Assessment (HTA) Coordination Group, the European Commission,…
Parliament puts final stamp on the European Health data Space
On April 24, the European Parliament gave its final endorsement to the regulation on the European Health Data Space (EHDS).
EU Parliament agrees on pharmaceutical legislation stance
On April 10, the European Parliament adopted its position on the revision of the EU pharmaceutical legislation.
Cancer Medicines Forum workshop April 5: a way forward for treatment optimizatio…
The Cancer Medicines Forum (CMF) is hosted by the European Medicines Agency (EMA) in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC).
Helping to shape Europe’s clinical trials landscape: EHA selected for ACT EU adv…
Improving the design, efficiency and effectiveness of clinical trials is the objective of the Accelerating Clinical Trials in the European Union (ACT EU) initiative.
EHA response to the EU’s Pharma Revision
Last week, the European Affairs team finalised EHA's response to the proposed revision of the EU (European Union) Pharmaceutical Legislation.
Hematology and oncology, pacemakers for EU HTA
EHA’s Martin Kaiser, right, addressing his fellow panelists. Left to right: Brian Cuffel (Bayer), Caroline Pothet (EMA), Roisin Adams (HTA CG), Bernhard Wörmann (DGHO) and Elisabeth de Vries (ESMO).
EHA in EU-funded project on voluntary plasma collection capacity in Europe
EHA to participate in an EU-funded project on “Strengthening voluntary non-remunerated plasma collection capacity in Europe” (SUPPLY) Context: Plasma shortage Plasma-derived medicinal products (PDMPs) are used to treat a variety of rare,…
EHA to the European Commission and HTA leaders: work with medical societies to i…
The speakers of the HTA conference hosted by the European Commission.
New EU In Vitro Diagnostic medical devices Regulation (IVDR) comes into effect
On May 26, 2022, the new EU In Vitro Diagnostic medical devices Regulation (IVDR) came into effect, mandating stricter and more comprehensive certification and testing protocols for in vitro diagnostic…
EU funding approved for TOLERATE
On April 1, the European Commission approved funding for the TOLERATE training network, proposed by a KU Leuven-led consortium including EHA.